Fundz

Viracta Therapeutics, Inc. reported raising $16.8 Million in an initial SEC Form D filing, from an offering of $25 Million

PRIVATENov 05, 2019$16.8M of $25M raised

Amount Raised

$16.8 Million

$16.8 Million sold, per SEC Form D (first sale Nov 5, 2019)

Round Type

Venture

Cardiff By The SeaInformation TechnologyBiotechnologyHealth CareScience And Engineering

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Viracta Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Advanced NanoTherapies raised $640K (Seed) on December 9, 2019.
  • Viome raised $36M on November 27, 2019.
  • Cardurion Pharmaceuticals raised $128M on November 20, 2019.
  • Vyriad raised $24M on November 14, 2019.
  • RedHill Biopharma Ltd raised $48M on November 6, 2019.
  • Cardiff Oncology raised $5M on October 30, 2019.

Who to call at Viracta Therapeutics, and when

A new round usually means Viracta Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Viracta Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Viracta Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Viracta Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Viracta Therapeutics

Location

Cardiff By The Sea, California, United States

About

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma and one Phase 1b/2 trial in patients with EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Viracta Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts56 people are listed at Viracta Therapeutics. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Viracta Therapeutics's next move

See what Strategic adds

Viracta Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.